Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Johncilla M, Jessurun J, Brown I, Hornick JL, Bellizzi AM, Shia J, et al. Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis? Am J Surg Pathol. 2018;42(10):1390-1395.

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.

Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31(5):791-808.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.

Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).

Zhai Y, Song W, Zeng J, Zhao Z, Cao Z. A 31-Year-Old Woman with Consecutive Pregnancy Losses. Clin Chem. 2018;64(5):777-780.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.

Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Soshnev AA, Josefowicz SZ, C Allis D. Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol Cell. 2018;69(3):533.